藥理學(xué)與化學(xué)生物學(xué)學(xué)科是我國(guó)最早的博士學(xué)位授予點(diǎn)之一,，也是國(guó)家第一批臨床藥理學(xué)研究基地,。在金正均教授等一批德高望重的老前輩的創(chuàng)建和指引下,，藥理學(xué)與化學(xué)生物學(xué)學(xué)科規(guī)模逐漸發(fā)展,，成為國(guó)家“211工程”、“985工程”和上海市“雙一流”暨“地方高水平建設(shè)項(xiàng)目”重點(diǎn)學(xué)科,，“藥理與毒理學(xué)”ESI排名位居全球前1‰行列,。
學(xué)科堅(jiān)持人才為先，育引并舉的策略,，一大批中青年優(yōu)秀教師和科研學(xué)術(shù)骨干脫穎而出,，形成了一支和諧,、充滿干勁和凝聚力的創(chuàng)新團(tuán)隊(duì)，在建設(shè)中不斷育引優(yōu)秀人才,，在教學(xué)與科研并重發(fā)展中造就創(chuàng)新人才,，逐步形成“集聚、適變,、開放,、共贏”文化氛圍。與加拿大多倫多大學(xué),、美國(guó)明尼蘇達(dá)大學(xué),、澳大利亞莫納什大學(xué)、法國(guó)巴黎五大,、巴黎七大和里昂一大等建立了密切的學(xué)術(shù)與人員交流合作,，不斷提升學(xué)科的學(xué)術(shù)競(jìng)爭(zhēng)力和國(guó)際化水平。
學(xué)科目前共有人員35人,，其中高級(jí)職稱人員27人,，包含10位PI研究人員，國(guó)務(wù)院學(xué)科評(píng)議組成員1人,，國(guó)家高層次人才計(jì)劃2人,，國(guó)家高層次人才計(jì)劃青年項(xiàng)目3人，國(guó)家自然科學(xué)基金會(huì)優(yōu)秀青年基金獲得者2人,， 上海市優(yōu)秀學(xué)科帶頭人2人,，上海市高層次人才計(jì)劃2人,，上海市高層次人才計(jì)劃青年項(xiàng)目2人,，上海市科技啟明星3人，上海市浦江人才3人,，上海市曙光計(jì)劃3人,，上海市衛(wèi)生系統(tǒng)銀蛇獎(jiǎng)提名獎(jiǎng)1人，上海市五一勞動(dòng)獎(jiǎng)?wù)?人等,。
學(xué)科圍繞生物醫(yī)藥前沿領(lǐng)域和國(guó)家科技戰(zhàn)略需求開展藥理學(xué),、化學(xué)生物學(xué)、納米藥物遞送和轉(zhuǎn)化醫(yī)學(xué)研究,。主要包括神經(jīng)退行性病,、腫瘤和心腦血管疾病新靶點(diǎn)發(fā)現(xiàn)和創(chuàng)新藥物研發(fā)，藥物動(dòng)力學(xué)和藥物代謝組學(xué)研究,，基于疾病功能基因組學(xué)信息的化學(xué)生物學(xué)研究和重大慢病防治的新藥與創(chuàng)新生物技術(shù)的臨床轉(zhuǎn)化等,。近五年，主持國(guó)家重點(diǎn)基礎(chǔ)研究（973計(jì)劃）課題3項(xiàng),、國(guó)家“重大新藥創(chuàng)制”重大專項(xiàng)5項(xiàng),、科技部國(guó)際科技合作專項(xiàng)4項(xiàng),，國(guó)家自然科學(xué)基金項(xiàng)目56項(xiàng)以及上海市重大/重點(diǎn)課題等13項(xiàng)。先后在Nature Medinice,，Nature Communication,，Cell Metabolism，PNAS,，Advanced Science,，ACS nano，Nano Letters,，Mol Pharmacol等國(guó)際權(quán)威期刊上發(fā)表論文200余篇,。其中2021年度最新研究成果先后在Science Translational Medicine、Cell Death & Differentiation,、Advanced Science,、Nano-Micro Letters等國(guó)際高水平期刊上發(fā)表，相關(guān)成果申請(qǐng)發(fā)明專利10項(xiàng),，已授權(quán)6項(xiàng),。2項(xiàng)孵育轉(zhuǎn)化，1項(xiàng)阿爾茨海默病干預(yù)新療法正在開展I/IIa臨床試驗(yàn),，2個(gè)創(chuàng)新制劑技術(shù)平臺(tái)入選上藥-交醫(yī)創(chuàng)新成果孵化項(xiàng)目,，協(xié)同復(fù)旦大學(xué)合作轉(zhuǎn)化原創(chuàng)抗腫瘤新藥項(xiàng)目1項(xiàng)。成果獲教育部科技技術(shù)進(jìn)步獎(jiǎng)一等獎(jiǎng),、上海市科學(xué)技術(shù)獎(jiǎng)一等獎(jiǎng),、教育部自然科學(xué)獎(jiǎng)二等獎(jiǎng)、上海醫(yī)學(xué)科技獎(jiǎng)二等獎(jiǎng)和中華醫(yī)學(xué)科技獎(jiǎng)二等獎(jiǎng)等,，擁有自主知識(shí)產(chǎn)權(quán)的國(guó)家“重大新藥創(chuàng)制”在研新藥2個(gè),。
學(xué)科支撐上海市轉(zhuǎn)化醫(yī)學(xué)協(xié)同創(chuàng)新中心、國(guó)家藥品臨床試驗(yàn)機(jī)構(gòu)I期臨床藥物動(dòng)力學(xué)研究室,、國(guó)家科技部精神神經(jīng)新藥GCP平臺(tái)藥物代謝組學(xué)和藥動(dòng)學(xué)實(shí)驗(yàn)室以及上海市高校系統(tǒng)藥理學(xué)重點(diǎn)實(shí)驗(yàn)室等,。擁有多個(gè)實(shí)驗(yàn)平臺(tái)，包括分子影像學(xué)平臺(tái),，由共聚焦顯微鏡,、熒光顯微鏡等構(gòu)成，滿足在各種層次分析細(xì)胞影像的需求,；藥動(dòng)學(xué)與代謝組學(xué)平臺(tái),，由多臺(tái)超高效液相色譜串聯(lián)三重四極桿質(zhì)譜及高分辨質(zhì)譜構(gòu)成，能夠完成臨床藥物代謝動(dòng)力學(xué),、代謝組學(xué),、脂質(zhì)組學(xué)等分析實(shí)驗(yàn)；動(dòng)物行為學(xué)實(shí)驗(yàn)平臺(tái),，由水迷宮,、曠場(chǎng)等行為學(xué)儀器及分析軟件等構(gòu)成,，能夠完成動(dòng)物學(xué)習(xí)記憶、情緒及運(yùn)動(dòng)行為分析等實(shí)驗(yàn),；小動(dòng)物影像平臺(tái),，由全自動(dòng)腦立體定位系統(tǒng)、小動(dòng)物PET/CT等構(gòu)成,，為利用動(dòng)物模型進(jìn)行研究提供了保障,；藥物靶標(biāo)發(fā)現(xiàn)與新藥篩選平臺(tái)，由BIACORE分子互作,、ITC等溫滴定量熱儀,、Flexstation III鈣流分析儀、PHERAstar,、FDSS高速成像分析儀等組成,，為新靶標(biāo)的發(fā)展與驗(yàn)證以及分子、細(xì)胞水平的高通量篩選及活性測(cè)定提供了充分條件,；化學(xué)信息學(xué)與生物信息學(xué)平臺(tái),，由中央隨機(jī)化系統(tǒng)、電子數(shù)據(jù)采集與查詢管理系統(tǒng)和統(tǒng)計(jì)分析系統(tǒng)等組成,，實(shí)現(xiàn)了更高效便捷的進(jìn)行數(shù)據(jù),、計(jì)算和圖形等資源共享，方便了信息處理工作的進(jìn)行,；納米生物學(xué)平臺(tái),，由粒度儀、超速離心系統(tǒng)等納米生物學(xué)相關(guān)設(shè)備構(gòu)成,，為開展納米生物學(xué)研究提供了條件,。上述實(shí)驗(yàn)平臺(tái)均有專業(yè)技術(shù)人員管理和操作，確?？蒲泄ぷ鞯捻樌_展,。
Discipline of Pharmacology and Chemical Biology
The Discipline of Pharmacology and Chemical Biology is one of the earliest doctoral degree awarding points in China, and it is also the first batch of China clinical pharmacology research bases. Established by and under the guidance of a group of highly respected senior researchers such as Professor Jin Zhengjun, the scale of Discipline of Pharmacology and Chemical Biology has gradually expended and the academic level is continuously improved. It is listed in the China National “211 Project” and “985 Project” and Shanghai Key Subject of “Double First Class”and "Local High-Level Construction Project". The ESI of "Pharmacology and Toxicology" ranks the top 1‰in the world.
The Discipline adheres to the strategy of Talent First with Fostering Talents from Inside as well as Introducing Talents from Outside. A large number of outstanding young teachers and scientific researching academics stand out, forming a harmonious, energetic and cohesive innovation team. During the development process, the Discipline continuously attracts and fosters excellent talents, creating innovative talented people in the atmosphere of paying equal attention to scientific research and teaching, and gradually forms a cultural of “Aggregation, Adaptability, Openness, and Win-Win”. The Discipline has established close academic and personnel exchanging and cooperation relationships with University of Toronto, University of Minnesota, Monash University, Paris Descartes University, Paris Diderot University – Paris 7 and Claude Bernard University Lyon 1, etc., and is constantly improving the academic competitiveness and internationalization level.
The discipline currently has a total of 35 personnel, including 27 senior titles, including 10 PI researchers. There are 1 member from the China State Council Discipline Review Group, 2 members from National High-level Talent Plan, 3 members from National High-level Youth Talent Plan, 2 Outstanding Young Fund winners of the National Natural Science Foundation of China, 2 Shanghai Outstanding Academic Leaders, 2 Shanghai High-level Talent Program, 2 Shanghai High-level Youth Talent Program, 3 members from Shanghai Science and Technology Development Funds, 3 members from Shanghai Pujiang Talent Plan, 3 members from Shanghai Dawn Program, 1 nomination of Shanghai Health System Silver Snake Award and 1 prize-winner of Shanghai Labor Medal, etc.
The subject aims at the frontier fields of biomedicine and national scientific and technological strategy needs to carry out pharmacology, chemical biology, nano drug delivery and translational medical research, mainly including the discovery of new targets for neurodegenerative diseases, tumors and cardio-cerebrovascular diseases and the development of innovative drugs, drug power research on pharmacology and drug metabolomics, chemical biology research based on disease functional genomics information and clinical transformation of new drugs and innovative biotechnology for the prevention and treatment of major chronic diseases. In the past five years, the Discipline has presided over 3 National Programs on Key Basic Research Projects (973 Program), 5 major projects of the National “Major New Drug Creation Projects”, 4 international science and technology cooperation special projects of the Ministry of Science and Technology of P.R.C., 56 projects of the National Natural Science Foundation of China, 13 major/key Shanghai science and technology projects. It has published more than 200 papers in internationally high-profile journals such as Nature Medinice, Nature Communication, Cell Metabolism, PNAS, Advanced Science, ACS nano, Nano Letters, Mol Pharmacol, etc. Among them, the latest research achievements in 2021 have been published in Science Translational Medicine, Cell Death & Differentiation, Advanced Science and Nano-Micro Letters and other international high-level journals. 10 invention patents have been applied for and 6 of them have been authorized. There are two incubation and transformation programs, one Alzheimer's disease intervention and new therapy program undergoing I/IIa clinical trials, two innovative preparation technology platforms selected into the innovation achievement incubation programs, and one original anti-tumor new drug program cooperated with Fudan University. The scientific research achievements win the First Prize of Science and Technology Progress of Ministry of Education, the First Prize of Shanghai Science and Technology Progress Award, the Second Prize of Natural Science of Ministry of Education, the Second Prize of Shanghai Medical Science and Technology Award, and the Second Prize of Chinese Medical Science and Technology. It has two researching new drugs with independent intellectual property rights of the national "New Major Drug Creation".
The Discipline of Pharmacology and Chemical Biology supports Shanghai Collaborative Innovation Center for Translational Medicine, Phase I Clinical Pharmacokinetics Laboratory of the National Drug Clinical Trial Institute, Pharmacokinetics and Pharmacokinetics Laboratory of the New Neuropsychiatric Drug GCP Platform of the Ministry of Science and Technology, and Shanghai University System Pharmacology Key Laboratory etc. The subject has multiple experimental platforms, including molecular imaging platforms, composed of confocal microscopes, fluorescent microscopes, etc., to meet the needs of analyzing cellular images at various levels; pharmacokinetic and metabolomics platforms, consisting of multiple ultra-high performance liquid phases Chromatography tandem triple quadrupole mass spectrometry and high-resolution mass spectrometry can be used to complete clinical pharmacokinetics, metabolomics, lipidomics and other analytical experiments; animal behavioral experiment platform is composed of water maze, open field and other behavioral instruments and The analysis software and other components can complete the experiments of animal learning and memory, emotion and sports behavior analysis; The small animal imaging platform is composed of a fully automatic brain stereo positioning system and small animal PET / CT, etc., which provides a guarantee for the use of animal models for research; drug target discovery and new drug screening platform, by BIACORE molecular interaction, ITC isothermal titration The instrument, Flexstation III calcium flow analyzer, PHERAstar, FDSS high-speed imaging analyzer, etc., provide sufficient conditions for the development and verification of new targets and high-throughput screening and activity determination at the molecular and cellular levels; Chemoinformatics and Bioinformatics Platform is composed of a central randomization system, an electronic data collection and query management system, and a statistical analysis system,，it realizes more efficient and convenient resource sharing of data, calculations, and graphics, and facilitates the process of information processing; nanobiology platform consists of nanometer biology related equipment such as particle size analyzer and ultracentrifuge system, which provides the conditions for carrying out nanobiology research. The above experimental platforms are managed and operated by professional technicians to ensure the smooth development of scientific research.
